<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138849</url>
  </required_header>
  <id_info>
    <org_study_id>BBT877-IPF-003</org_study_id>
    <nct_id>NCT04138849</nct_id>
  </id_info>
  <brief_title>Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 Following Single Doses in Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bridge Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRN Research, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bridge Biotherapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect safety, pharmacokinetic, and pharmacodynamic data in Japanese male&#xD;
      subjects in order to support development worldwide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">October 25, 2019</completion_date>
  <primary_completion_date type="Actual">October 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to Day 14.</time_frame>
    <description>The number of AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics_AUC (the area under the curve)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>AUC of BBT-877</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics_Cmax (peak concentration)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Cmax of BBT-877</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics_plasma LPA (Lysophosphatidic acid)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>plasma LPA (18:2 and 20:4) concentrations over time and percent decrease from baseline LPA level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>BBT-877 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BBT-877 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BBT-877 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBT-877 single dose</intervention_name>
    <description>Oral capsule, single dose.</description>
    <arm_group_label>BBT-877 High Dose</arm_group_label>
    <arm_group_label>BBT-877 Low Dose</arm_group_label>
    <arm_group_label>BBT-877 Mid Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo single dose</intervention_name>
    <description>Oral capsule, single dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent form as described in Appendix 3 which includes compliance&#xD;
             with the requirements and restrictions listed in the informed consent form (ICF) and&#xD;
             in this protocol&#xD;
&#xD;
          2. Healthy male 18 to 55 years of age inclusive at the time of signing the informed&#xD;
             consent form&#xD;
&#xD;
          3. Continuous non-smoker who has not used nicotine-containing products for at least 3&#xD;
             months prior to dosing and throughout the study.&#xD;
&#xD;
          4. Overtly healthy as determined by medical evaluation including medical history,&#xD;
             physical examination, clinical laboratory tests&#xD;
&#xD;
          5. Body mass index (BMI) within 18 to 30.0 kg/m2 (inclusive) and body weight not less&#xD;
             than 50 kg&#xD;
&#xD;
          6. Blood pressure (after supine for 5 minutes) between 90 and 140 mmHg systolic,&#xD;
             inclusive, and no higher than 90 mmHg diastolic.&#xD;
&#xD;
          7. A 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and&#xD;
             function.&#xD;
&#xD;
          8. Must agree to use contraception as detailed in Appendix 5 of this protocol during the&#xD;
             treatment period and for at least 90 days after dosing of study treatment and refrain&#xD;
             from donating sperm during this period&#xD;
&#xD;
          9. Be first generation Japanese.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a history of or current clinically significant medical illness that the&#xD;
             investigator considers should exclude the subject or that could interfere with the&#xD;
             interpretation of the study results.&#xD;
&#xD;
          2. Clinically significant abnormal values for hematology, clinical chemistry, or&#xD;
             urinalysis at screening and Day -1 as deemed appropriate by the investigator&#xD;
&#xD;
          3. Clinically significant abnormal physical examination, vital signs or 12 lead ECG at&#xD;
             screening and Day -1 as deemed appropriate by the investigator&#xD;
&#xD;
          4. Has donated blood or had a significant blood loss (â‰¤500 mL) within 8 weeks of Day 1 or&#xD;
             history of anemia or history of decreased red blood cells (RBC).&#xD;
&#xD;
          5. Donated plasma within 7 days of Day -1&#xD;
&#xD;
          6. Estimated creatinine clearance &lt;80 mL/min&#xD;
&#xD;
          7. Liver function tests (serum alkaline phosphatase [ALP], aspartate transaminase [AST],&#xD;
             alanine aminotransferase [ALT]) and serum bilirubin (total and direct) 1.2 times above&#xD;
             the upper limit of normal (ULN) at Screening or Day -1.&#xD;
&#xD;
          8. Baseline hemoglobin, hematocrit, red blood cell count below the lower limit of normal&#xD;
             at Screening and Day -1.&#xD;
&#xD;
          9. Has a history of human immunodeficiency virus (HIV) antibody positive, or tests&#xD;
             positive for HIV; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C&#xD;
             antibody (anti-HCV) positive, or other clinically active liver disease, or tests&#xD;
             positive for HBsAg or anti-HCV at Screening.&#xD;
&#xD;
         10. History of drug or alcohol abuse according to Diagnostic and Statistical Manual of&#xD;
             Mental Disorders (4th edition) criteria within 5 years before screening or positive&#xD;
             test result(s) for alcohol and/or drugs of abuse at screening and Day -1.&#xD;
&#xD;
         11. Positive cotinine test at Screening and Day -1.&#xD;
&#xD;
         12. History of presence of hypersensitivity or idiosyncratic reaction to the study drug(s)&#xD;
             or related compounds.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Hyun Ryou, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Bridge Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

